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Treatment of patients with IgA nephropathy (IgAN) depends
on a reliable assessment of disease progression based on
measurements of glomerular filtration rate (GFR), proteinuria,
hypertension, and tubulointerstitial changes. We sought to
determine whether progression could be predicted from
analysis of glomerular and tubulointerstitial inflammation in
biopsies taken at an early stage of IgAN. We retrospectively
analyzed biopsies from 50 patients, relating the subsequent
clinical course to infiltration with B- and T-lymphocytes,
granule membrane protein of 17kDa (GMP-17) positive
cytotoxic T cells, macrophages, fibroblasts, and
tubulointerstitial expression of human leukocyte antigen-D
related (HLA-DR). At biopsy, 19 patients had decreased GFR
while 13 of 31 patients with normal GFR and progressive
IgAN differed significantly from 18 non-progressors in the
level of proteinuria and in the severity of scores for mesangial
proliferation, tubular atrophy, interstitial fibrosis, and
interstitial infiltrates. On multivariate regression analysis
these differences disappeared; however, associations with
GMP-17-positive cytotoxic T-lymphocytes in intact renal
tubules and of B-lymphocytes in the interstitium remained
significant. Our study may have identified a marker of disease
progression in early stages of IgAN.
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The course of primary IgA nephropathy (IgAN) is character-
ized by a variable rate of progression.1 Even without
treatment, a few patients may have a complete remission,
whereas others may need renal replacement therapy within a
few years after presentation. All other patients have clinical
courses between these two extremes. The actuarial renal
survival rate at 10 years varies between 62 and 96% in
different studies, depending on what disease stages are
included.2 Biopsy policy has been strongly influenced by its
therapeutic consequences. The treatment of IgAN has long
been controversial. Recent studies have shown that cytotoxic
treatment of IgAN patients will stabilize a declining renal
function in a subset of patients.3 Treatment with cortico-
steroids will maintain renal function in patients with normal
glomerular filtration rate (GFR) and proteinuria in excess
of 1 g 24 h1.4 However, some patients with this level of
proteinuria will maintain their renal function without
immunosuppressive treatment.
Most Western centers restrict their biopsy policy to
patients with an impaired GFR. This policy selects patients
at the highest risk of progression, but it has at least two
disadvantages. First, it intervenes late in the course of the
disease, and second, stabilization is frequently transient in
patients with a GFR below 60mlmin1.3 This restricted
biopsy policy impairs progress in the early detection of
patients with a normal GFR who will progress to renal failure.
The ideal strategy would be to identify those patients
who will progress to renal failure as early as possible. The
detection of markers at an early stage of IgAN would facilitate
early therapeutic intervention before irreversible damage has
occurred.
The purpose of this study was to search for markers of
progression in renal biopsies of IgAN patients with normal
GFR. Generally, tubulointerstitial changes predict progres-
sion more accurately than the glomerular changes.5,6 The
transition of the initial glomerular inflammation into a
chronic, progressive tubulointerstitial process is thought to
be mediated by development of tubulointerstitial infiltrate.
It is hypothesized that patients who progress in the early
phase of IgAN differ, either qualitatively or quantitatively,
from non-progressing patients in the composition of the
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interstitial infiltrate. Evidence to this effect comes from
biopsies of progressors, who have more mononuclear leuko-
cytes and CD4- as well as CD8-positive lymphocytes in their
interstitium than biopsies from patients with stable function.7
We compared the leukocyte subpopulations in glomeruli and
tubulointerstitium of progressors and non-progressors in early
and later stages of their disease using immunohistochemistry.
The predictive values of these immunohistochemical para-
meters were compared with other known clinical and histo-
pathological parameters of progression.
RESULTS
Clinical and histopathological differences between
progressors and non-progressors
Clinical and histopathological differences between progres-
sors and non-progressors were compared in two groups;
in patients with a (near) normal estimated GFR (eGFR)
(group1, n¼ 31) and in patients with an impaired eGFR
(group 2, n¼ 19) at the time of biopsy. The duration of
follow up in both groups was shorter in progressors (Table 1)
because five patients in group 1 and 10 patients in group 2
developed terminal renal failure as the end point of follow
up. In group 1, the eGFR at the time of biopsy did not differ
between progressors and non-progressors, but progressors
had a higher level of proteinuria and higher scores for
mesangial proliferation, accumulation of mesangial matrix,
tubular atrophy, interstitial fibrosis, and interstitial infiltrate.
The histological scores for tubulitis in intact and in atrophic
tubules did not differ in either group. Patients with
interstitial fibrosis, tubular atrophy, and interstitial infiltrate
had higher progression rates than patients without these
tubulointerstitial changes (Figure 1). Progressors in group 2
differed only from non-progressors in the scores for
interstitial fibrosis (Table 1).
Immunohistochemistry in IgAN patients with eGFR
X60mlmin1 (group 1)
Glomeruli of progressors and non-progressors with eGFR
460mlmin1 did not differ in the number of CD45-, CD3-,
CD4-, CD8-, CD20-, CD68-, or granule membrane protein
17 (GMP-17)-positive cells (data not shown). The inter-
stitium of progressors showed higher scores for CD45-,
CD3-, CD4-, CD20-, human leukocyte antigen-D related
(HLA-DR)-, and a-smooth-muscle actin (a-SMA)-positive
Table 1 | Clinical and histopathological differences between progressors and non-progressors with eGFR X60mlmin1 or
o60mlmin1 at the time of biopsy
eGFR X60mlmin1 eGFR o60mlmin1
Progressors (n=13) Non-progressors (n=18) P-value Progressors (n=14) Non-progressors (n=5) P-value
Follow-up (years) 8.6±5.1 14.5±6.9 o0.05 6.9±4.5 12.0±5.3 0.085
Age (years) 35.6±12.8 31.2±9.5 0.47 48.8±16.6 42.6±11.7 0.56
Sex (males) 11 (85%) 14 (78%) 1.0 12 (86%) 5 (100%) 1.0
eGFR (mlmin1) 80.8±22.9 84.4±16.1 0.34 44.9±11.7 50.4±6.1 0.39
Proteinuria (41 g 24 h1) 11 (85%) 7 (39%) o0.05 13 (100%) 3 (60%) 0.065
Hypertension 7 (54%) 7 (39%) 0.48 10 (71%) 2 (40%) 0.31
Mesangial proliferation 2.15±0.9 1.4±0.9 o0.05 1.9±0.9 1.6±1.3 0.66
Matrix accumulation 1.3±1.0 0.6±1.0 o0.05 1.2±1.0 1.2±0.8 1.00
Tubular atrophy 1.3±0.9 0.2±0.4 0.001 2.0±0.8 1.4±0.5 0.18
Interstitial fibrosis 1.3±1.0 0.4±0.6 o0.05 2.2±0.7 1.2±0.8 o0.05
Interstitial infiltrates 1.1±0.9 0.2±0.4 o0.005 2.0±0.8 1.6±0.5 0.48
Tubulitis in intact tubules 1.0±0.9 0.9±0.8 0.78 1.30±0.8 0.8±0.4 0.26
Tubulitis in atrophic tubules 1.1±0.9 0.8±1.0 0.27 1.9±1.0 1.0±1.2 0.18
eGFR, estimated glomerular filtration rate.
Significant P-values are indicated as bold faced.
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Figure 1 | Interstitial histopathological characteristics of progressors vs non-progressors. The progression rate of each individual
patient in group 1 with eGFR above 60mlmin1 is expressed in relation to the presence or absence of interstitial fibrosis (a), tubular atrophy
(b), and interstitial infiltration (c). The horizontal dotted line separates the progressors (progression rate X0.2 year1) from
non-progressors (progression rate o0.2 year1).
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cells (Table 2). The intra-epithelial scores for CD3 and
HLA-DR were also higher in progressors. Biopsies were also
screened for the presence of cytotoxic T-lymphocytes by
staining CD8-positive lymphocytes for the GMP-17 cytotoxic
marker. Progressors had significantly higher scores for GMP-
17/CD8-positive lymphocytes in the interstitium as well as in
tubules compared with non-progressors (Table 2). Repre-
sentative pictures of the significant differences for CD45,
CD3, CD20, and a-SMA are shown in Figure 2. The different
expression of HLA-DR, CD8/GMP-17, and GMP-17/SR are
shown in Figure 3. Six biopsies with the highest scores for
intra-epithelial GMP-17-positive T-lymphocytes were double
stained for CD8 and granzyme B or CD8 and perforin.
Representative pictures are shown in the Supplementary
Figure 1, together with the negative controls. These results
were negative (data not shown) and therefore they were not
further pursued. The progression rate of patients with
GMP-17/CD8-positive lymphocytes in their interstitium
(Figure 4a) or within their tubules (Figure 4b) was
significantly higher than in patients who did not have these
tubulointerstitial markers of inflammation. Since the intra-
epithelial scores differed from the interstitial scores, it became
crucial to distinguish clearly between the two compartments.
The intra-epithelial localization in the GMP-17/CD8-stained
sections was not always unequivocal (Figure 3c). Therefore,
GMP-17-stained sections were counterstained with Sirius
Red (SR) to accentuate the tubular basement membrane
(Figures 2e and f). In addition, this counterstain allowed
lymphocytes within intact tubules to be distinguished from
lymphocytes in atrophic tubules. Progressors had higher
scores for GMP-17/SR in the interstitium and in intact renal
tubules than non-progressors(Table 2; Figure 3e). The
progression rate of patients with GMP-17-positive lympho-
cytes in the interstitium (Figure 4c) and within the intact
tubules (Figure 4d) was significantly higher. In patients with
eGFR o60mlmin1, non-progressors and progressors did
not differ for these immunohistochemical markers, except for
a higher score for CD4 in the tubules of non-progressors.
Predictive values and likelihood ratios in patients with eGFR
460mlmin1
Proteinuria above 0.5 g 24 h1 has an excellent negative
predictive value, but a poorer positive predictive value and
a low likelihood ratio (Table 3). Proteinuria above 1 g 24 h1
does not improve these predictors. The same applies to the
histopathological parameters of the glomeruli. The predictive
values for tubular atrophy and for interstitial infiltrate were
higher with a likelihood ratio of 4.15 for interstitial infiltrate.
The presence of CD3-positive T-lymphocytes within tubules,
the expression of HLA-DR by infiltrating leucocytes in the
interstitium and by renal tubules improved the predictability
of progression. Especially the presence of CD20-positive
B-lymphocytes in the interstitium increased the predictability
with a likelihood ratio of 9.85. When CD8-positive
T-lymphocytes were stained for GMP-17, positive predictive
values of 0.80 were found for interstitium and for renal
Table 2 | Scores (0–2) of various leukocyte subpopulations in the interstitium and tubules of progressors and non-progressors
with eGFR X60mlmin1 or o60mlmin1 at the time of biopsy
eGFR X60mlmin1 eGFR o60mlmin1
Leukocyte subpopulation Locationa Progressors Non-progressors P-value Progressors Non-progressors P-value
CD45 Interstitium 1.7±0.5 0.6±0.5 0.0005 1.9±0.4 1.4±0.9 0.40
Tubules 0.8±0.6 0.4±0.5 0.194 1.1±0.6 0.8±0.8 0.70
CD3 Interstitium 0.8±0.8 0.3±0.5 o0.05 1.3±0.6 1.2±0.8 0.99
Tubules 0.6±0.5 0.1±0.3 o0.005 1.0±0.9 0.6±0.6 0.52
CD4 Interstitium 0.1±0.3 0.7±0.7 o0.01 1.0±0.9 1.4±0.9 0.56
Tubules 0.1±0.3 0.0 0.41 0.1±0.4 1.0±1.0 0.028
CD20 Interstitium 0.8±0.7 0.1±0.2 o0.005 1.1±0.7 1.0±0.7 0.89
CD68 Interstitium 0.3±0.6 0.1±0.3 0.52 1.1±0.9 0.6±0.6 0.34
Tubules 0.1±0.3 0.1±0.2 1.00 0.1±0.4 0.2±0.4 0.89
HLA-DR Interstitium 1.2±0.8 0.2±0.6 o0.005 1.7±0.5 1.6±0.5 0.75
Tubules 1.0±0.6 0.2±0.4 0.001 1.6±0.5 1.6±0.5 1.0
a-SMA Interstitium 1.3±0.9 0.6±0.6 o0.05 1.8±0.4 2.0±0 0.52
CD8/GMP-17 Interstitium 0.8±0.8 0.1±0.3 o0.005 1.2±0.7 1.2±0.8 1.00
Tubules 1.0±0.4 0.2±0.4 o0.0001 1.4±0.5 0.8±0.8 0.21
GMP-17/SR Interstitium 0.7±0.7 0.0 o0.005 1.2±0.7 0.6±0.9 0.19
Intact tubules 1.2±0.6 0.2±0.5 o0.0001 1.3±0.5 0.8±0.4 0.11
Atrophic tubules 0.9±0.6 0.1±0.2 o0.0005 1.3±0.7 1.0±0.7 0.51
eGFR, estimated glomerular filtration rate; HLA-DR, human leukocyte antigen-D receptor; a-SMA, a-smooth-muscle actin; SR, Sirius Red.
aGlomeruli did not show significant differences in the scores for leucocyte subpopulations.
Significant P-values are indicated as bold faced.
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tubules, whereas absence of cytotoxic T-lymphocytes in
renal tubules excluded progression in 94% of cases. The
SR stain allowed us to not only distinguish between
lymphocytes in the interstitium as opposed to renal tubules,
but also between lymphocytes in normal-appearing or intact
tubules as opposed to atrophic tubules. The correlation
between these two tubular scores was highly significant
(Po0.0001). The interstitial scores of GMP-17/SR provided
for the highest positive predictive value, but a negative
predictive value of 0.78. The likelihood ratio could not be
calculated because specificity was 1. The presence of
GMP-17-positive lymphocytes in intact renal tubules pre-
dicted for progression in 86% of patients, whereas its absence
predicted for a stable renal function in 94% of patients.
In patients with eGFRo60mlmin1, progressors and non-
progressors did not differ for these immunohistochemical
markers, except for a higher score for CD4 in tubules of
non-progressors.
Weighted univariate and multivariate regression analysis
The characterization of progression as a decline of the slope
greater than 0.2 units per year is rather arbitrary. The slope of
decline of eGFR was studied as a continuous variable in
weighted univariate and subsequent multivariate regression
analysis. In univariate analysis, clinical parameters such as
eGFR and proteinuria were not significant (Table 4).
However, tubular atrophy and interstitial infiltrate were
significantly associated with progression. This association
disappeared on multivariate regression analysis, whereas
interstitial CD20 and intra-epithelial GMP-17/CD8 remained
significant. Interstitial and intra-epithelial staining of GMP-
17/CD8 and GMP-17/SR were highly correlated.
DISCUSSION
This study shows that the identification of cytotoxic
T-lymphocytes in the interstitium and within renal tubules
can predict for progression toward renal failure in IgAN
patients with normal or near-normal GFR. The positive and
negative predictive values of this immunohistochemical
predictor are higher than those of conventional clinical and
histopathological predictors such as proteinuria, interstitial
fibrosis, tubular atrophy, and interstitial infiltrate. After
Figure 2 |Phenotype of infiltrating leukocytes. Progressors
express CD45 (a), CD3 (c), CD20 (e), and a-SMA (g) in their biopsies.
Arrows indicate intra-epithelial lymphocytes (c). CD45-positive
leucocytes (a), CD20-positive B cells (e), and a-SMA are located in
the interstitium. The images from non-progressors (b, d, f, h) do not
show these abnormalities.
Figure 3 |Phenotype and localizations of cytotoxic T-cells.
HLA-DR expressed in proximal tubules in a biopsy of a progressor
(a). CD8- (in red) and GMP-17 (in black)-positive cytotoxic
T-lymphocytes within tubules (open arrows) and in the interstitium
(closed arrows) of a progressor (b). The exact localization of double
positive cells was sometimes unclear (c) (arrow with asterisk).
The tubular basement membrane is delineated by the use of SR
(e, f) to distinguish between intra-epithelial and interstitial
GMP-17-positive (in black) lymphocytes. The images from
non-progressors (b, d, f) do not show these abnormalities.
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multiple regression analysis, only intraepithelial GMP-17-
positive T-lymphocytes and interstitial B-lymphocytes were
associated with progression in patients with normal or near-
normal eGFR (Table 4). In patients with impaired GFR,
presence of intraepithelial cytotoxic T-lymphocytes was no
longer a marker for progression. Apparently progression
must have occurred at some stage in these patients. It
occurred at the time of biopsy, but may have been
intermittently present. Intra-epithelial lymphocytes were
described earlier in renal tubules,6 but the nature of these
cells and their relationship to progression has not been
investigated. The histopathological score of tubulitis in intact
or in atrophic tubules in our study was not associated with
progression (Table 1). Analysis of interstitial infiltrate by
immunohistochemical staining improved the predictability
for risk of progression. Especially staining of cytotoxic
T-lymphocytes in renal tubules for CD3 and CD8/GMP-17
resulted in our study in high predictive values and likelihood
ratios (Table 3). The use of the GMP-17 marker probably
identified a subpopulation of cytotoxic T-lymphocytes more
specifically than the intra-epithelial lymphocytes recognized
by light microscopy. GMP-17 is a 17-kDa granular membrane
protein that was previously designated as TIA-1. Its
expression is restricted to cytotoxic T-lymphocytes and
natural killer cells.8 GMP-17/CD56- and GMP-17/CD16-
positive natural killer cells could not be detected within renal
tubules (data not shown). The concurrent positive staining of
GMP-17 and CD8 in our study suggests that the intratubular
lymphocytes are cytotoxic T-lymphocytes rather than natural
killer cells. Upon recognition of its target cell, GMP-17
expression is strongly upregulated in cytoplasmic granules
and the protein is transported to the plasma membrane for
release.9 The clinical relevance of GMP-17 was first shown in
inflammatory bowel disease.10 The detection of GMP-17 in
interstitial T-lymphocytes does not necessarily imply that
these cells are activated. However, intraepithelial location of
these cells strongly suggests that these cells are actively
attracted to their target antigens. Furthermore, cytotoxic T-
lymphocytes were not only seen in normal looking tubules,
but also in atrophic and fragmented tubules, suggesting a
cytopathic effect of these lymphocytes on tubules. Intra-
epithelial lymphocytes were not only seen in the proximity
of interstitial infiltrate, but were also seen in the absence
of interstitial infiltrate. Six of the 14 patients with GMP-17-
positive T-lymphocytes in intact tubules did not have these
cells in the interstitium. This suggests that these intraepithe-
lial lymphocytes are not the consequence of an abundant
infiltrate in the proximity of renal tubules, but that the
T-lymphocytes may find their intratubular target indepen-
dent of the amount of interstitial infiltrate. It also suggests
that the attack of these cytotoxic T-lymphocytes on renal
tubules or tubulitis is responsible for the deterioration of
renal function in these patients. Myllyma¨ki et al.11 have
shown that tubulo-interstitial expression of CD45 and CD3,
together with the expression of interleukin-1b and inter-
leukin-10, was associated with progression. Only 12 of the
204 patients in this study initially had normal GFR and no
attempt was made to correlate intraepithelial lymphocytes
with progression. The high likelihood ratio of interstitial
CD20-positive B-lymphocytes in our study is in agreement
with an earlier study of seven progressors in a total of 17
patients with normal GFR.12 Recently, these cells were
characterized as mature memory B cells expressing the
receptor for CXCL13.13
None of our patients were treated with immunosuppres-
sion or corticosteroids. Although our study was not designed
to study the effect of treatment with angiotensin II
antagonists, all five non-progressing patients with impaired
GFR received angiotensin-converting enzyme inhibitors. On
the other hand, of the 13 progressors with normal GFR at
biopsy, nine were on angiotensin-converting enzyme inhibi-
tors at the end of follow up. In the group of patients with
impaired GFR, tubulitis was very common irrespective of the
rate of decline. This suggests that tubulitis is not only active
in early and progressive IgAN, but also when the course of
the disease is more indolent.
Although the number of patients in our study is limited, it
should be noted that also in larger studies the number of
patients with normal GFR are limited due to biopsy policy.
Despite limited numbers, highly significant predictive values
were obtained for the association between progression and
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Figure 4 |Correlation of cytotoxic T-cells with progression. The
progression rate of each individual patient in group 1 with eGFR
above 60mlmin1 is expressed in relation to the presence or
absence of CD8/GMP-17-positive lymphocytes in the interstitium (a)
or in renal tubules (b). The relationship of progression rate to absence
or presence of GMP-17-positive T-lymphocytes in the interstitium or
in intact renal tubules using SR as a counterstain is shown in (c) and
(d), respectively. The horizontal dotted line separates the progressors
(progression rate X0.2 year1) from non-progressors (progression
rate o0.2 year1).
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immunohistochemical manifestations of tubulitis. After our
observation has been confirmed independently, the presence
or absence of tubulitis could indicate, together with other
parameters, which patient with normal GFR should be
treated and which patient can be expected to have stable
function without treatment.
MATERIALS AND METHODS
Patient selection
The renal biopsies from all patients with IgAN obtained between
1983 and 2001 were retrieved from the archives of the Department
of Pathology. Children below the age of 14 years and patients with
IgA myeloma, liver disease, or any systemic disease were excluded.
Patients with Henoch–Schoenlein purpura or rapidly progressive
IgAN were also excluded. All other biopsies were included, provided
that yearly serum creatinine measurements and sufficient cortex for
further immunohistochemical studies were available. Two patients
were lost to follow up. Body weight, blood pressure, serum
creatinine, and protein excretion per 24 h at the time of biopsy
were recorded. Patients were considered hypertensive when they
used antihypertensive medication at the time of biopsy. The use of
angiotensin-converting enzyme inhibitors or angiotensin II receptor
blockers (collectively designated as angiotensin II antagonists) was
registered separately. None of the patients received corticosteroids or
other immunosuppression. GFR was estimated (eGFR) using the
modification of diet in renal disease (MDRD) 2 equation.14 Patients
were categorized into a group with normal or mild decrease in
eGFR (X60mlmin1 1.73m2) and a group with impaired eGFR
(o60mlmin1 1.73m2). Progression was expressed as the slope of
regression of 1000 divided by serum creatinine values measured
yearly.15 Progressors were defined as patients with a decline greater
than 0.2 year1.
Histopathological studies
Biopsy sections were stained with hematoxylin–eosin, periodic
acid–Schiff, and silver methenamine. Glomerular, tubular,
Table 3 | Sensitivity, specificity, predictive values, and likelihood ratios of clinical, histopathological, and immunohistochemical
parameters with regard to progression toward renal failure in patients with eGFR X60mlmin1
Sensitivity Specificity Positive predictive value Negative predictive value Likelihood ratio
Proteinuria X0.5 g 24 h1 1.0 0.56 0.62 1.0 2.25
Proteinuria X1 g 24 h1 0.85 0.61 0.61 0.85 2.18
Mesangial proliferation 0.92 0.17 0.44 0.75 1.11
Matrix accumulation 0.77 0.61 0.59 0.79 2.00
Tubular atrophy 0.77 0.78 0.71 0.82 3.46
Interstitial infiltrate 0.69 0.83 0.75 0.79 4.15
CD45 Interstitium 1.0 0.39 0.54 1.0 1.63
Tubules 0.69 0.56 0.53 0.71 1.56
CD3 Interstitium 0.62 0.72 0.62 0.72 2.21
Tubules 0.62 0.89 0.89 0.76 5.54
CD4 Interstitium 0.54 0.89 0.78 0.73 4.85
CD20 Interstitium 0.62 0.94 0.89 0.75 9.85
a-SMA Interstitium 0.77 0.50 0.53 0.75 1.54
HLA-DR Interstitium 0.77 0.82 0.77 0.82 4.36
Tubules 0.85 0.82 0.79 0.87 4.80
CD8/GMP-17 Interstitium 0.62 0.89 0.80 0.76 5.54
Tubules 0.92 0.83 0.80 0.94 5.54
GMP-17/SR Interstitium 0.62 1.0 1.0 0.78
Intact tubules 0.92 0.89 0.86 0.94 8.31
Atrophic tubules 0.77 0.94 0.91 0.85 13.85
eGFR, estimated glomerular filtration rate; HLA-DR, human leukocyte antigen-D receptor; a-SMA, a-smooth-muscle actin; SR, Sirius Red.
Table 4 | Regression coefficients, confidence intervals, and
P-values of clinical, histopathological, and immunohistochemical
predictors of progression in IgAN patients with (near) normal
eGFR
Predictors
Slope (regression
coefficient)
Confidence
interval P-value
Univariate
eGFR 0.005 0.016 to +0.006 0.345
Proteinuria +0.090 0.242 to +0.422 0.582
Tubular atrophy +0.382 +0.045 to +0.720 0.028
Interstitial infiltrate +0.372 +0.022 to +0.722 0.038
CD20 interstitium +1.423 +0.711 to +1.775 o0.0005
GMP-17/CD8
interstitium
+0.362 +0.010 to +0713 0.044
GMP-17/CD8
intra-epithelial
+0.378 +0.680 to +0.689 0.019
Multivariate
CD20 interstitium +1.180 +0.602 to +0.1.633 o0.0005
GMP-17/CD8
intra-epithelial
+0.266 +0.007 to +0.526 0.045
eGFR, estimated glomerular filtration rate; IgAN, IgA nephropathy.
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interstitial, and vascular abnormalities were scored by a single renal
pathologist who was blinded to other information in the study. The
total number of glomeruli, the number of globally sclerosed
glomeruli, and the number of glomeruli with focal segmental
sclerosis, ischemia, and crescents were counted and expressed as a
percentage of the total number of glomeruli. A semi-quantitative
scoring system (0–3) was used to score mesangial proliferation,
mesangial matrix accumulation, interstitial infiltration, and arterial
hyalinosis. Tubular atrophy, interstitial fibrosis, and tubulitis were
scored according to the Banff ’97 working classification.16 The
severity of tubulitis was recorded separately for areas with intact
tubules and for areas with atrophic tubules.
Immunohistochemical studies
Biopsies specimens were stained for markers of leukocytes (CD45),
T-lymphocytes (CD3, CD4, CD8), B-lymphocytes (CD20), macro-
phages (CD68), cytotoxic T-lymphocytes (GMP-17), HLA-DR, and
interstitial fibroblasts (a-SMA) as follows. Sections measuring 4 mm
were deparaffinized in 96% ethanol, blocked for endogenous
peroxidases in a mixture of 1ml of 30% H2O2 in 250ml of
methanol for 20min, and subsequently hydrated in decreasing
ethanol concentrations. Antigen retrieval was not required for CD45
or for a-SMA staining. For CD3, CD8/GMP-17, and CD20 staining,
antigen retrieval was performed by boiling sections in 10mM citrate
buffer pH 6 for 10min. For CD4 and GMP-17, stained sections were
boiled in 1mM ethylene diamine tetraacetic acid pH 9 for 12min.
Antigen retrieval for CD68 was performed by incubation in 0.1%
trypsin solution with 0.1% CaCl2 at 371C for 15min. HLA-DR
staining was performed by boiling the sections in 1mM Tris/ethylene
diamine tetraacetic acid pH 9 for 10min. Sections were then
incubated with antibodies directed against CD45 (clone2B11; Dako,
Glostrup, Denmark), CD3 (polyclonal antibody A0452; Dako), CD4
(cloneNCl-1F6; Nova Castra, Newcastle, UK), CD20 (M-0755
IgG2a-k clone L26; Dako), CD68 (M0814 IgG1k clone KP-1; Dako),
GMP-17 (2550 IM IgG clone 2G9; Immunotech, Marseille, France),
HLA-DR (MO746, clone TAL-1B5; Dako), a-SMA (61001, IgG2a
clone ASM-1, Progen; Biotechnik, Heidelberg, Germany), and
granzyme B (clone GrB; Monosan-Sanbio, Uden, Belgium) or
perforin (MS1834-50, clone 5B10; Lab Vision, Fremont, CA, USA).
Binding of these primary antibodies was visualized using horse-
radish peroxidase-labeled anti-mouse or anti-rabbit antibodies
(Envision; Dako), and a mixture of 3,3 aminobenzidine (0.05%)
and NiCl2 (0.07%). Binding of anti-CD8 antibodies (SP16; Lab
Vision) was visualized with alkaline phosphatase-labeled anti-rabbit
antibodies and Fast Red substrate. Sections were rinsed between
each step with phosphate-buffered saline. Hematoxylin was used as
counterstain.
Sections from donor kidneys unsuitable for transplantation were
used as negative controls. Sections from tonsils and kidneys with
rejection were used as positive controls for leukocyte markers. Ileal
biopsies from a patient with Crohn’s disease were used to control for
adequate GMP-17 staining. Staining of infiltrating cells in the
interstitium was scored in three categories: 0, no or occasionally
positive cells; 1, positive cells diffusely present in the interstitium or
one positive focus of infiltrate; and 2, two or more positive foci or
diffuse interstitial infiltrate with one focus. Intra-epithelial cells were
scored as follows: 0, no cells or one cell within renal tubules in the
whole section; 1, two to three positive cells within tubules; and 2,
four or more positive cells. For a-SMA, scoring was as follows: 0,
staining exclusively in blood vessels; 1, focal (o50%), and 2, diffuse
(450%) staining of the interstitium.
Statistical analysis
For comparisons of interval variables between progressors and non-
progressors, Student’s independent-sample t-test was used. When
statistical assumptions for parametric analysis of interval variables
were not met and in case of ordinal data, Mann–Whitney’s two-
independent sample test was used. Nominal (categorical) variables
were analyzed using cross-tables and exact P-values were calculated.
Two-by-two cross-tables were created to calculate sensitivity,
specificity, and predictive value to assess the accuracy of positive
and negative tests. To study the relationship between progression
rate and clinical, histological, as well as immunohistochemical
parameters, stepwise weighted least-square univariate and multi-
variate regression analysis was used. To account for differences in
measurement accuracy, the inverse of variance of slope terms for
each individual case was used as a weighting factor. All analyses were
performed using SPSS statistical software package (version 10.07;
SPSS Inc., Chicago, IL, USA). To calculate sensitivity, specificity, and
predictive values, GraphPad Prism version 4.00 for Windows
(GraphPad Software, San Diego, CA, USA; www.graphpad.com)
was used.
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SUPPLEMENTARY MATERIAL
Figure S1. Progressors did not differ in the expression of granzyme B
(A) or perforin (C) compared with non-progressors (B and D,
respectively).
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